US1000075A
(en)
|
1910-07-27 |
1911-08-08 |
William R Collins |
Tunneling-machine.
|
US4694778A
(en)
|
1984-05-04 |
1987-09-22 |
Anicon, Inc. |
Chemical vapor deposition wafer boat
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
DE3650699T2
(de)
|
1985-03-15 |
1999-04-15 |
Antivirals Inc |
Immunotestmittel für Polynukleotid und Verfahren
|
US4828971A
(en)
|
1988-03-24 |
1989-05-09 |
Eastman Kodak Company |
Thermally processable element comprising a backing layer
|
CA1251835A
(fr)
|
1988-04-05 |
1989-03-28 |
Wai-Cheung Tang |
Multiplexeur a resonateurs images dielectriques
|
WO1991004753A1
(fr)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
|
ES2061416T3
(es)
|
1990-10-12 |
1997-03-01 |
Max Planck Gesellschaft |
Ribozimas modificadas.
|
DE4216134A1
(de)
|
1991-06-20 |
1992-12-24 |
Europ Lab Molekularbiolog |
Synthetische katalytische oligonukleotidstrukturen
|
US5652094A
(en)
|
1992-01-31 |
1997-07-29 |
University Of Montreal |
Nucleozymes
|
KR100361933B1
(ko)
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
US5627053A
(en)
|
1994-03-29 |
1997-05-06 |
Ribozyme Pharmaceuticals, Inc. |
2'deoxy-2'-alkylnucleotide containing nucleic acid
|
WO1995035287A1
(fr)
|
1994-06-17 |
1995-12-28 |
F.Hoffmann-La Roche Ag |
Derives n,n'-bis(quinolin-4-yle)-diamine, leur preparation et leur utilisation en tant qu'antipaludeens
|
US5716824A
(en)
|
1995-04-20 |
1998-02-10 |
Ribozyme Pharmaceuticals, Inc. |
2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
|
US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
WO1997026270A2
(fr)
|
1996-01-16 |
1997-07-24 |
Ribozyme Pharmaceuticals, Inc. |
Synthese de methoxy nucleosides et de molecules d'acide nucleique enzymatique
|
WO1997034631A1
(fr)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Domaines analogues a l'immunoglobuline a demi-vies prolongees
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
EP0963443B1
(fr)
|
1996-12-10 |
2006-03-08 |
Sequenom, Inc. |
Molecules d'etiquetage massique, non volatiles et liberables
|
US20030073207A1
(en)
|
1997-01-31 |
2003-04-17 |
Saghir Akhtar |
Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
US6111086A
(en)
|
1998-02-27 |
2000-08-29 |
Scaringe; Stephen A. |
Orthoester protecting groups
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
EP1071753A2
(fr)
|
1998-04-20 |
2001-01-31 |
Ribozyme Pharmaceuticals, Inc. |
Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
|
GB9816575D0
(en)
|
1998-07-31 |
1998-09-30 |
Zeneca Ltd |
Novel compounds
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
ATE350012T1
(de)
|
1999-02-22 |
2007-01-15 |
Univ Georgetown |
Immunoliposome mit einem targeting- antikörperfragment zur systemischen genverabreichung
|
US6849272B1
(en)
|
1999-04-21 |
2005-02-01 |
Massachusetts Institute Of Technology |
Endosomolytic agents and cell delivery systems
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
CA2328356A1
(fr)
|
1999-12-22 |
2001-06-22 |
Itty Atcravi |
Vehicules recreatifs
|
JP2003531821A
(ja)
|
1999-12-29 |
2003-10-28 |
イムノージェン インコーポレーテッド |
改変型ドキソルビシンおよびダウノルビシンを含む細胞傷害性薬剤ならびにその治療上の使用
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
EP2345742B1
(fr)
|
2000-03-30 |
2014-06-11 |
The Whitehead Institute for Biomedical Research |
Médiateurs spécifiques de la séquence d'ARN d'interférence d'ARN
|
DK2361981T4
(da)
|
2000-03-30 |
2019-05-13 |
The Whitehead Institute For Biomedical Res |
Rna-sekvensspecifikke mediatorer af rna-interferens
|
KR20020097241A
(ko)
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
JP2002095476A
(ja)
|
2000-09-20 |
2002-04-02 |
Eisai Co Ltd |
トランスフェリン受容体を介した遺伝子導入法
|
ES2728168T3
(es)
*
|
2000-12-01 |
2019-10-22 |
Max Planck Gesellschaft |
Moléculas pequeñas de ARN que median en la interferencia de ARN
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
DE10133858A1
(de)
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
US6942972B2
(en)
|
2001-10-24 |
2005-09-13 |
Beckman Coulter, Inc. |
Efficient synthesis of protein-oligonucleotide conjugates
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20040023220A1
(en)
|
2002-07-23 |
2004-02-05 |
Lawrence Greenfield |
Integrated method for PCR cleanup and oligonucleotide removal
|
MXPA05001355A
(es)
|
2002-08-05 |
2005-09-30 |
Atugen Ag |
Formas nuevas adicionales de moleculas de arn de interferencia.
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
WO2006006948A2
(fr)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
WO2004090105A2
(fr)
|
2003-04-02 |
2004-10-21 |
Dharmacon, Inc. |
Polynucleotides modifies utilisables pour l'interference arn
|
WO2004100987A2
(fr)
*
|
2003-05-06 |
2004-11-25 |
Regeneron Pharmaceuticals, Inc. |
Procede d'utilisation d'antagonistes de l'il1 pour le traitement d'hyperplasie neointimale
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
WO2005001043A2
(fr)
|
2003-06-02 |
2005-01-06 |
University Of Massachusetts |
Methodes et compostions permettant d'ameliorer l'efficacite et la specificite d'une interference d'arn
|
PL1633767T3
(pl)
|
2003-06-02 |
2019-07-31 |
University Of Massachusetts |
Sposoby i kompozycje do kontrolowania wydajności wyciszania rna
|
EP1633770B1
(fr)
|
2003-06-13 |
2015-04-29 |
Alnylam Europe AG |
Acide ribonucleique double brin presentant une efficacite accrue dans un organisme
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
KR101438983B1
(ko)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
US7494925B2
(en)
|
2004-02-23 |
2009-02-24 |
Micron Technology, Inc. |
Method for making through-hole conductors for semiconductor substrates
|
US8389710B2
(en)
|
2004-02-27 |
2013-03-05 |
Operational Technologies Corporation |
Therapeutic nucleic acid-3′-conjugates
|
US8084599B2
(en)
|
2004-03-15 |
2011-12-27 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
EP1765847A4
(fr)
|
2004-05-27 |
2010-10-20 |
Alnylam Pharmaceuticals Inc |
Acide ribonucleique double brin resistant aux nucleases
|
EP3228711A1
(fr)
|
2004-06-28 |
2017-10-11 |
The University Of Western Australia |
Oligonucléotides antisens permettant d'induire un saut d'exon et leurs procédés d'utilisation
|
WO2006132670A2
(fr)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatines comportant une unite d'acide aminobenzoique au n-terminal
|
US7429482B2
(en)
*
|
2005-01-13 |
2008-09-30 |
United States Of America As Represented By The Department Of Veterans Affairs |
Screening tools for discovery of novel anabolic agents
|
KR101363120B1
(ko)
|
2005-02-10 |
2014-02-13 |
베일러 리서치 인스티튜트 |
항-인터페론 알파 모노클로날 항체 및 사용 방법
|
CA2610027A1
(fr)
|
2005-05-26 |
2006-11-30 |
Ensemble Discovery Corporation |
Biodetection reposant sur la chimie a base de matrices d'acides nucleiques
|
US20070054259A1
(en)
*
|
2005-06-17 |
2007-03-08 |
City Of Hope |
Modulation of hnRNP H and treatment of DM1
|
AU2006280600B2
(en)
|
2005-08-17 |
2012-01-19 |
Bioneer Corporation |
Sirna-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
|
EP1937312B1
(fr)
|
2005-08-30 |
2016-06-29 |
Ionis Pharmaceuticals, Inc. |
Composés oligomériques chimériques pour la modulation de l'epissage
|
WO2007121272A2
(fr)
*
|
2006-04-11 |
2007-10-25 |
The Board Of Regents Of The University Of Texas System |
Procédé et compositions concernant des troubles à base de séquences nucléotidiques répétées
|
HUE035799T2
(en)
|
2006-05-10 |
2018-05-28 |
Sarepta Therapeutics Inc |
Cationic oligonucleotide analogues containing subunits
|
EP1857548A1
(fr)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Procédé et moyen permettant d'induire un saut d'exon
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
US7521232B2
(en)
|
2006-05-31 |
2009-04-21 |
Icx Nomadics, Inc. |
Emissive species for clinical imaging
|
KR101196184B1
(ko)
|
2006-06-02 |
2012-11-01 |
아베오 파마슈티컬즈, 인크. |
간세포 성장 인자 (hgf) 결합 단백질
|
WO2008008315A2
(fr)
|
2006-07-10 |
2008-01-17 |
Biogen Idec Ma Inc. |
COMPOSITIONS ET MÉTHODES VISANT À INHIBER LA CROISSANCE DE CANCERS À DÉFICIENCE EN smad4
|
WO2008018795A1
(fr)
|
2006-08-11 |
2008-02-14 |
Prosensa Technologies B.V. |
Procédés et moyens de traitement de troubles génétiques associés à l'instabilité des répétitions de l'ADN
|
WO2008022309A2
(fr)
|
2006-08-18 |
2008-02-21 |
F. Hoffmann-La Roche Ag |
Polyconjugués pour l'administration in vivo de polynucléotides
|
CA2735166C
(fr)
|
2007-08-27 |
2020-12-01 |
Boston Biomedical, Inc. |
Compositions d'arn interferent asymetrique et leurs utilisations
|
CN101809283B
(zh)
|
2007-08-29 |
2012-07-25 |
维斯塔斯风力系统集团公司 |
用于离岸风力发电机的单桩地基
|
JP2010538678A
(ja)
|
2007-09-18 |
2010-12-16 |
イントラドイグム コーポレーション |
K−rassiRNA含有組成物及びそれらの使用法
|
DK2195428T3
(en)
|
2007-09-19 |
2014-03-03 |
Applied Biosystems Llc |
SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF
|
PT2203173E
(pt)
|
2007-10-26 |
2016-03-15 |
Academisch Ziekenhuis Leiden |
Resumo
|
US20110065774A1
(en)
|
2008-01-31 |
2011-03-17 |
Alnylam Pharmaceuticals |
Chemically modified oligonucleotides and uses thereof
|
WO2009099991A2
(fr)
|
2008-01-31 |
2009-08-13 |
The Brigham And Women's Hospital, Inc. |
Traitement du cancer
|
BRPI0906643A2
(pt)
|
2008-02-01 |
2019-09-10 |
Ascendis Pharma As |
profármaco compreendendo um conjugado fármaco-ligante
|
EP3643782A1
(fr)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Polynucléotides d'arni modifiés et leurs utilisations
|
PL2842575T3
(pl)
|
2008-03-18 |
2018-02-28 |
Seattle Genetics, Inc. |
Koniugaty aurystatyny lek łącznik
|
JP5788312B2
(ja)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
|
CA2720363A1
(fr)
|
2008-04-15 |
2009-10-22 |
Bira Arya |
Compositions et procedes pour fournir des oligonucleotides inhibiteurs
|
US8248352B2
(en)
|
2008-04-25 |
2012-08-21 |
Lg Display Co., Ltd. |
Driving circuit of liquid crystal display
|
EP2119783A1
(fr)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
JP5583667B2
(ja)
|
2008-08-08 |
2014-09-03 |
ジェニスフィア・エルエルシー |
長時間作用型dnaデンドリマーおよびその方法
|
EP2323628B1
(fr)
|
2008-08-13 |
2022-04-13 |
California Institute of Technology |
Nanoparticules de support et compositions, procédés et systèmes apparentés
|
WO2010028054A1
(fr)
|
2008-09-02 |
2010-03-11 |
Alnylam Europe Ag. |
Compositions et procédés d'inhibition de l'expression d'un gène egfr mutant
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
US8664189B2
(en)
|
2008-09-22 |
2014-03-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in skin indications
|
CN105779453A
(zh)
|
2008-10-24 |
2016-07-20 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
SI2607484T1
(sl)
|
2008-10-27 |
2016-11-30 |
Biomarin Technologies B.V. |
Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
|
KR101602431B1
(ko)
|
2008-11-05 |
2016-03-10 |
삼성전자 주식회사 |
냉장고
|
WO2010064146A2
(fr)
|
2008-12-02 |
2010-06-10 |
Chiralgen, Ltd. |
Procédé pour la synthèse d’acides nucléiques modifiés par des atomes de phosphore
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
US8481698B2
(en)
|
2009-03-19 |
2013-07-09 |
The President And Fellows Of Harvard College |
Parallel proximity ligation event analysis
|
CA2757354A1
(fr)
|
2009-04-02 |
2010-10-07 |
Laura P.W. Ranum |
Polypeptides associes a des expansions de repetitions nucleotidiques et leurs utilisations
|
CN102459595A
(zh)
|
2009-04-24 |
2012-05-16 |
普罗森那技术公司 |
用于治疗dmd的包含肌苷的寡核苷酸
|
BRPI1011269A2
(pt)
|
2009-05-05 |
2016-09-27 |
Altermune Technologies Llc |
imunidade quimicamente programável
|
PL2896404T3
(pl)
|
2009-06-04 |
2017-12-29 |
Novartis Ag |
Sposoby identyfikacji miejsc koniugacji IgG
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
WO2011003780A1
(fr)
|
2009-07-06 |
2011-01-13 |
F. Hoffmann-La Roche Ag |
Anticorps bispécifiques de liaison à la digoxygénine
|
WO2011009624A1
(fr)
|
2009-07-22 |
2011-01-27 |
Cenix Bioscience Gmbh |
Système d'administration et conjugués pour l'administration de composés par des voies de transport intracellulaire naturelles
|
WO2011024077A2
(fr)
|
2009-08-31 |
2011-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Thérapie par saut exon pour amélioration fonctionnelle de la dystrophine semi-fonctionnelle dans la dystrophie musculaire de duchenne et becker
|
WO2011044368A1
(fr)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Polypeptides contenant une région fc qui présentent une fonction d'effecteur améliorée due à des modifications de l'étendue de la fucosylation, et leurs méthodes d'utilisation
|
JP5963678B2
(ja)
|
2009-11-12 |
2016-08-03 |
ジ ユニバーシティ オブ ウェスタン オーストラリア |
病状を治療するためのアンチセンス分子及び方法
|
EP2534174A4
(fr)
|
2010-02-12 |
2015-02-25 |
Solulink Inc |
Préparation et/ou purification de conjugués d'oligonucléotides
|
NZ602933A
(en)
|
2010-04-15 |
2014-09-26 |
Seattle Genetics Inc |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
BR112012026801B8
(pt)
|
2010-04-15 |
2021-05-25 |
Medimmune Ltd |
conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
|
CA2799501C
(fr)
|
2010-05-28 |
2022-02-15 |
Sarepta Therapeutics, Inc. |
Analogues oligonucleotidiques ayant des liaisons modifiees entre sous-unites et/ou des groupes terminaux modifies
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
CA2802089A1
(fr)
|
2010-06-11 |
2011-12-15 |
Antisense Pharma Gmbh |
Procede pour une modification selective d'oligonucleotides
|
EP3031920B1
(fr)
*
|
2010-07-19 |
2019-08-21 |
Ionis Pharmaceuticals, Inc. |
Modulation de l'expression d'une dystrophia myotonica-protéine kinase
|
CN103068853B
(zh)
|
2010-08-19 |
2016-08-10 |
Peg生物制药公司 |
协同性生物分子-聚合物轭合物
|
EP3327125B1
(fr)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
AU2011352204B2
(en)
|
2010-12-29 |
2015-05-21 |
Arrowhead Pharmaceuticals, Inc. |
In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
|
JP2014507143A
(ja)
|
2011-02-08 |
2014-03-27 |
ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング/ビジネス/アズ キャロライナズ ヘルスケア システム |
アンチセンスオリゴヌクレオチド
|
US9045750B2
(en)
|
2011-03-18 |
2015-06-02 |
Yuelong Ma |
Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3
|
EP3590965A1
(fr)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Variants de fc d'anticorps
|
CA2839593A1
(fr)
|
2011-07-15 |
2013-01-24 |
Sarepta Therapeutics, Inc. |
Procedes et compositions pour manipulation de la traduction d'isoformes de proteines a partir de sites initiateurs alternatifs d'initiation
|
JP6128529B2
(ja)
|
2011-07-19 |
2017-05-17 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
官能化核酸の合成のための方法
|
US9418216B2
(en)
|
2011-07-21 |
2016-08-16 |
Microsoft Technology Licensing, Llc |
Cloud service authentication
|
EP3640332A1
(fr)
|
2011-08-29 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Complexes oligomères-conjugués et leur utilisation
|
WO2013055990A1
(fr)
|
2011-10-14 |
2013-04-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazépines et conjugués ciblés
|
WO2013071079A1
(fr)
|
2011-11-09 |
2013-05-16 |
President And Fellows Of Harvard College |
Structures cristallines de lin-28/let-7, protocoles de purification, et sondes moléculaires appropriées pour des tests de criblage et des substances thérapeutiques
|
KR102534909B1
(ko)
|
2011-11-18 |
2023-05-30 |
알닐람 파마슈티칼스 인코포레이티드 |
변형된 RNAi 제제
|
GB201121069D0
(en)
*
|
2011-12-07 |
2012-01-18 |
Isis Innovation |
Delivery system
|
WO2013103800A1
(fr)
|
2012-01-06 |
2013-07-11 |
Bioalliance C.V. |
Anticorps de récepteur d'anti-transferrine et leurs procédés
|
EP2814512A1
(fr)
|
2012-02-16 |
2014-12-24 |
UCL Business Plc. |
Lieur clivable par des lysosomes
|
US9814782B2
(en)
|
2012-02-24 |
2017-11-14 |
Alteogen Inc. |
Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
|
CA2907072A1
(fr)
*
|
2012-03-16 |
2013-09-19 |
Valerion Therapeutics, Llc |
Conjugues antisens destines a diminuer l'expression du dmpk
|
AR090905A1
(es)
|
2012-05-02 |
2014-12-17 |
Merck Sharp & Dohme |
Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
|
WO2013166004A2
(fr)
|
2012-05-02 |
2013-11-07 |
Novartis Ag |
Compositions organiques pour traiter des maladies associées à kras
|
WO2013173393A1
(fr)
|
2012-05-15 |
2013-11-21 |
Concortis Biosystems, Corp |
Conjugués médicamenteux, procédés de conjugaison et utilisations de ceux-ci
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
JP6453212B2
(ja)
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
キラル制御
|
CA2880869A1
(fr)
|
2012-08-20 |
2014-02-27 |
The Regents Of The University Of California |
Polynucleotides possedant des groupes bioreversibles
|
EP2839860B1
(fr)
|
2012-10-12 |
2019-05-01 |
MedImmune Limited |
Pyrrolobenzodiazépines et ses conjugués
|
AU2013346767B2
(en)
|
2012-11-15 |
2019-04-11 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
EP2922818B1
(fr)
|
2012-11-24 |
2018-09-05 |
Hangzhou Dac Biotech Co., Ltd |
Lieurs hydrophiles et leurs utilisations pour la conjugaison de médicaments à des molécules se liant aux cellules
|
CN105102455B
(zh)
|
2012-12-21 |
2018-05-25 |
荷商台医(有限合伙)公司 |
亲水性自消耗连接子及其缀合物
|
US9481905B2
(en)
|
2013-02-19 |
2016-11-01 |
Orizhan Bioscience Limited |
Method of using neutrilized DNA (N-DNA) as surface probe for high throughput detection platform
|
US9319764B2
(en)
|
2013-03-08 |
2016-04-19 |
Merry Electronics Co., Ltd. |
MEMS microphone packaging structure
|
JP6449231B2
(ja)
|
2013-03-14 |
2019-01-09 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィを処置するためのエキソンスキッピング組成物
|
BR112015022585B1
(pt)
|
2013-03-15 |
2023-04-04 |
Regeneron Pharmaceuticals, Inc |
Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos
|
EP2777714A1
(fr)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Procédé de production d'un conjugué de ligand immunologique/charge utile à l'aide d'une enzyme transpeptidase spécifique pour une séquence
|
MX2015013117A
(es)
|
2013-03-15 |
2016-07-14 |
Sarepta Therapeutics Inc |
Composiciones mejoradas para tratar distrofia muscular.
|
US9577459B2
(en)
|
2013-03-15 |
2017-02-21 |
Sequana Medical Ag |
Systems and methods for regulating inductive energy transfer to an implantable system
|
CN105378083B
(zh)
|
2013-03-27 |
2018-09-21 |
伊萨纳治疗有限公司 |
修饰的TGF-β寡核苷酸
|
US9295731B2
(en)
|
2013-04-01 |
2016-03-29 |
Mark Quang Nguyen |
Cleavable drug conjugates, compositions thereof and methods of use
|
US9861574B2
(en)
|
2013-04-09 |
2018-01-09 |
Duke University |
2-fluoro-modified RNAs as immunostimulators
|
JP2016520574A
(ja)
|
2013-04-28 |
2016-07-14 |
秦剛 |
新規リンカー、その製造方法およびその応用
|
CA2908743A1
(fr)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anticorps anti-recepteur de transferrine et procedes d'utilisation
|
CN105849129A
(zh)
|
2013-05-31 |
2016-08-10 |
酵活有限公司 |
具有降低的或沉默的效应子功能的异多聚体
|
WO2014197854A1
(fr)
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
EP2845607A1
(fr)
|
2013-09-09 |
2015-03-11 |
University of Vienna |
Oligonucléotides antisens ayant des propriétés pharmacocinétiques améliorées
|
WO2015038426A1
(fr)
|
2013-09-13 |
2015-03-19 |
Asana Biosciences, Llc |
Lieurs auto-immolables contenant des dérivés d'acide mandélique, conjugués médicament-ligand pour thérapies ciblées, et leurs utilisations
|
CN106132431A
(zh)
|
2013-10-15 |
2016-11-16 |
索伦托治疗有限公司 |
具有靶向分子和两种不同药物的药物偶联物
|
WO2015057699A2
(fr)
|
2013-10-15 |
2015-04-23 |
Seattle Genetics, Inc. |
Lieurs de médicaments pégylés pour pharmacocinétique de conjugués ligand-médicament améliorée
|
EP3065758B1
(fr)
|
2013-11-06 |
2019-09-25 |
Merck Sharp & Dohme Corp. |
Conjugués contenant des peptides pour double distribution moléculaire d'oligonucléotides
|
WO2015084846A1
(fr)
|
2013-12-02 |
2015-06-11 |
Brandeis University |
Sélection à température élevée de vaccins glucidiques soutenu par un nucléotide et oligonucléotides glycosylés en résultant
|
SG10201912897UA
(en)
|
2014-01-16 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral design
|
KR102287532B1
(ko)
|
2014-01-30 |
2021-08-11 |
에프. 호프만-라 로슈 아게 |
생분해성 컨쥬게이트를 갖는 폴리 올리고머 화합물
|
SG10201912858VA
(en)
|
2014-06-17 |
2020-02-27 |
Nippon Shinyaku Co Ltd |
Antisense nucleic acids
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
AU2015280252A1
(en)
|
2014-06-23 |
2017-01-12 |
Monsanto Technology Llc |
Compositions and methods for regulating gene expression via RNA interference
|
EP3186377A1
(fr)
|
2014-08-20 |
2017-07-05 |
Alnylam Pharmaceuticals, Inc. |
Agents d'arn double brin modifié
|
WO2016170348A2
(fr)
|
2015-04-22 |
2016-10-27 |
Mina Therapeutics Limited |
Compositions de petits arn et méthodes d'utilisation
|
US20180344817A1
(en)
|
2015-05-01 |
2018-12-06 |
Precision Biosciences, Inc. |
Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases
|
KR102644053B1
(ko)
|
2015-05-19 |
2024-03-06 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
펩티드 올리고뉴클레오티드 콘주게이트
|
RU2020124105A
(ru)
|
2015-06-24 |
2020-09-18 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
|
WO2017148880A1
(fr)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Variantes de l'obinutuzumab dont l'induction de l'apoptose est modifiée
|
MA45328A
(fr)
*
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
CN109310765A
(zh)
|
2016-06-20 |
2019-02-05 |
领先基因生物技术股份有限公司 |
抗体-药物偶联物
|
WO2018002812A1
(fr)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Matériels et méthodes de traitement de la dystrophie myotonique de type 1 (dm1) et d'autres troubles associés
|
US20190256868A1
(en)
|
2016-10-28 |
2019-08-22 |
Genethon |
Compositions and methods for the treatment of myotonic dystrophy
|
US11427824B2
(en)
|
2016-10-28 |
2022-08-30 |
Genethon |
Compositions and methods for the treatment of myotonic dystrophy
|
SG10202107429WA
(en)
|
2017-01-06 |
2021-08-30 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
IT201700008383A1
(it)
*
|
2017-01-26 |
2018-07-26 |
Explea S R L |
Dispositivo per la produzione di energia elettrica utilizzante l’azione combinata di campi magnetici pulsati e di correnti fluidodinamiche agenti su una lamina flessibile dotata di un elemento piezoelettrico ed impianto formato da più elementi modulari collegati elettricamente fra loro e composti ciascuno da una pluralità di tali dispositivi
|
AU2018261890A1
(en)
|
2017-05-05 |
2019-11-28 |
Centre For Probe Development And Commercialization |
IGF-1R monoclonal antibodies and uses thereof
|
JP2020537497A
(ja)
|
2017-09-22 |
2020-12-24 |
アビディティー バイオサイエンシーズ,インク. |
エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法
|
MX2020003596A
(es)
*
|
2017-10-04 |
2020-07-22 |
Avidity Biosciences Inc |
Composiciones de acido nucleico-polipeptido y usos de las mismos.
|
CA3083526A1
(fr)
|
2017-12-06 |
2019-06-13 |
Andrew John Geall |
Compositions et procedes de traitement de l'atrophie musculaire et de la dystrophie myotonique
|
CA3108335A1
(fr)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Complexes de ciblage musculaire et leurs utilisations
|
US11446387B2
(en)
|
2020-03-27 |
2022-09-20 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|